Overview
Smart money at a glance
Filings to Oct 4, 2026Net selling: insiders sold $1.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$1.6M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 4- Open
- $9.34
- 52-wk high
- $11.33
- High
- $9.34
- 52-wk low
- $5.25
- Low
- $9.04
- Prev close
- $9.25
- Mkt cap
- $1.66B
- Volume
- 1.80M
- Fwd P/E
- 36.9x
- Beta
- 0.85
- P/S
- 4.9x
- P/B
- 107.7x
- Profit margin
- -5.1%
- Op margin
- +5.6%
- ROE
- -617.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about XERS filings
Are insiders buying or selling Xeris Pharmaceuticals Inc (XERS) stock?
Net selling: insiders sold $1.6M and bought $0 of XERS stock on the open market in the 90 days to Oct 4, 2026, according to SEC Form 4 filings. $1.6M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was McCulloch, Kevin (See Remarks), who sold $639K. The latest filing was on Oct 2, 2026.
Which members of Congress have traded XERS recently?
None. No member of Congress disclosed a XERS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this XERS smart-money data?
This summary uses filings available on Oct 4, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- BO

Bank of America
$6.0M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in XERS right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.03 a share below what analysts expected.
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.02 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | -$0.01 / $0.02Alpha Vantage | -$0.03 miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 7, 2026 | $0.01 / -$0.01Alpha Vantage | +$0.02 beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 2, 2026 | $0.06 / $0.02Alpha Vantage | +$0.04 beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | $0.00 / $0.01Alpha Vantage | -$0.01 miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$0.01 / -$0.03Alpha Vantage | +$0.02 beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | -$0.06 / -$0.04Alpha Vantage | -$0.02 miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 6, 2025 | -$0.03 / -$0.02Alpha Vantage | -$0.01 miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 8, 2024 | -$0.06 / -$0.08Alpha Vantage | +$0.02 beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 32 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -5.1%
- Forward P/E
- 36.90
- Market cap
- $1.7B
Valuation
- P/S4.94
- P/B107.68
Quality
- Operating margin5.6%
- ROE-617.0%
- ROA6.1%
Growth
- Beta0.85
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace